Breaking News, Collaborations & Alliances

ViroCell Biologics Delivers Novel Retroviral Vector to AvenCell Therapeutics for Allogeneic CAR-T Therapy

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies.

Author Image

By: Charlie Sternberg

Associate Editor

ViroCell Biologics, a viral vector Contract Development and Manufacturing Organization (CDMO), has entered a manufacturing collaboration with AvenCell Therapeutics Inc., delivering a novel retroviral vector for AvenCell’s investigational CD19/CD20 dual-targeted cell therapy, AVC-203. The therapy, designed for B cell malignancies and autoimmune diseases, is slated to enter a phase I clinical trial for relapsed/refractory B cell lymphoma in the second half of 2025. AvenCell’s AVC-203 is an allo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters